Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 Oct 2019
Historique:
received: 06 04 2019
revised: 22 06 2019
accepted: 05 08 2019
pubmed: 20 8 2019
medline: 15 9 2020
entrez: 19 8 2019
Statut: ppublish

Résumé

Depression is considered one of the prodromal symptoms of Parkinson's disease (PD) along with sleep disorders, hyposmia and constipation. Prodromal symptoms refer to the stage wherein early motor symptoms and signs allowing a diagnosis of PD are not yet present. The objective of this study was to investigate the association between the use of antidepressants, as indirect measure of depression, and subsequent PD onset, clinically diagnosed, in the Local Health Trust of Bologna, Italy. Historical cohort study with use of antidepressants as exposure and PD onset as outcome. The cohort considered consisted of inhabitants of Bologna aged ≥35 years in 2005; those who had used antidepressants in the previous 3 years were excluded. Subjects were followed up from 2006 and until PD onset, migration out of Bologna, death or end of the study period (2017), whichever came first. "The ParkLink Bologna" system was used to detect disease onset. "ParkLink Bologna" is a research study including patients with a clinical diagnosis of PD residing in Bologna. Residents that used antidepressants for at least 180 consecutive days within 1 year were considered exposed. Hazard ratios (HR) and 95% confidence interval (CI) were estimated with Cox proportional hazards models, using exposure as time-dependent variable and adjusting for potential confounders: age, gender, use of medical care and comorbidities. From 2006 to 2017 199,093 person-years were exposed and 4,286,470 not exposed. Fifty-one subjects with PD were identified in the exposed group and 556 subjects in the non-exposed showing an association of adjusted HR = 1.7 (CI 1.3-2.3). The association was stronger for males (HR 2.2, CI 1.5-3.2) compared to females (HR 1.2, CI 0.8-1.9), for subjects ≤65 years of age (HR 2.4, CI 1.6-3.6) vs. >65 years (HR 1.3, CI 0.8-1.9) and for those with less comorbidities. Age and gender were confounders in the associations between antidepressant use and PD onset. The use of antidepressants as indirect measure of depression is associated with the subsequent development of PD. Our findings confirm that depression may precede the onset of motor symptoms in PD. The association is stronger for younger subjects, who are males and with fewer comorbidities.

Sections du résumé

BACKGROUND BACKGROUND
Depression is considered one of the prodromal symptoms of Parkinson's disease (PD) along with sleep disorders, hyposmia and constipation. Prodromal symptoms refer to the stage wherein early motor symptoms and signs allowing a diagnosis of PD are not yet present. The objective of this study was to investigate the association between the use of antidepressants, as indirect measure of depression, and subsequent PD onset, clinically diagnosed, in the Local Health Trust of Bologna, Italy.
METHODS METHODS
Historical cohort study with use of antidepressants as exposure and PD onset as outcome. The cohort considered consisted of inhabitants of Bologna aged ≥35 years in 2005; those who had used antidepressants in the previous 3 years were excluded. Subjects were followed up from 2006 and until PD onset, migration out of Bologna, death or end of the study period (2017), whichever came first. "The ParkLink Bologna" system was used to detect disease onset. "ParkLink Bologna" is a research study including patients with a clinical diagnosis of PD residing in Bologna. Residents that used antidepressants for at least 180 consecutive days within 1 year were considered exposed. Hazard ratios (HR) and 95% confidence interval (CI) were estimated with Cox proportional hazards models, using exposure as time-dependent variable and adjusting for potential confounders: age, gender, use of medical care and comorbidities.
RESULTS RESULTS
From 2006 to 2017 199,093 person-years were exposed and 4,286,470 not exposed. Fifty-one subjects with PD were identified in the exposed group and 556 subjects in the non-exposed showing an association of adjusted HR = 1.7 (CI 1.3-2.3). The association was stronger for males (HR 2.2, CI 1.5-3.2) compared to females (HR 1.2, CI 0.8-1.9), for subjects ≤65 years of age (HR 2.4, CI 1.6-3.6) vs. >65 years (HR 1.3, CI 0.8-1.9) and for those with less comorbidities. Age and gender were confounders in the associations between antidepressant use and PD onset.
CONCLUSIONS CONCLUSIONS
The use of antidepressants as indirect measure of depression is associated with the subsequent development of PD. Our findings confirm that depression may precede the onset of motor symptoms in PD. The association is stronger for younger subjects, who are males and with fewer comorbidities.

Identifiants

pubmed: 31422283
pii: S0022-510X(19)30342-9
doi: 10.1016/j.jns.2019.08.006
pii:
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116421

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Corrado Zenesini (C)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. Electronic address: c.zenesini@isnb.it.

Elisa Baldin (E)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Luca Vignatelli (L)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Elisabetta Poluzzi (E)

Pharmacology Unit, Department of Medical and Surgical Sciences, Università degli Studi di Bologna, Bologna, Italy.

Ippazio Antonazzo (I)

Pharmacology Unit, Department of Medical and Surgical Sciences, Università degli Studi di Bologna, Bologna, Italy.

Giovanna Calandra-Buonaura (G)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Departments of Biomedical and Neuromotor Sciences, Università degli Studi di Bologna, Italy.

Maria Guarino (M)

Neurology Unit, S. Orsola-Malpighi University Hospital, Bologna, Italy.

Piero De Carolis (P)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Pietro Cortelli (P)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; Departments of Biomedical and Neuromotor Sciences, Università degli Studi di Bologna, Italy.

Roberto D'Alessandro (R)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH